We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Autologous CAR T-Cell Manufacturing

Autologous CAR T-Cell Manufacturing content piece image

Cell-based chimeric antigen receptor (CAR) T-cell therapies have rapidly advanced from preclinical research. This success has driven an influx of companies to further develop CAR T-cell constructs to make them more effective, safe and persistent. On the manufacturing side, however, errors, lot-to-lot variation and contamination can be associated with open processing and manual handling of CAR T products. Overcoming the bioprocessing bottleneck remains a critical challenge in CAR T-cell therapy scalability, which can potentially hinder both product development and patient access.

Download this whitepaper to discover a method that is:

  • Consistently generating a pure and safe product
  • GMP compliant
  • Semi-automated